James Van Der Beek died at 48 after being diagnosed with colorectal cancer. Here's what to know about common symptoms, which can be subtle. [Business Insider]
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: Business Insider
This story is available exclusively to Business Insider subscribers. Become an Insider and start reading now. Have an account? Log in James Van Der Beek died at 48. He was diagnosed with stage 3 colorectal cancer in 2023. Cases are rising among people under 50, including those who live healthy lifestyles Van Der Beek advocated for getting screened, whether you get a Shield test or a colonoscopy. James Van Der Beek has died at 48. In 2023, the "Dawson's Creek" star learned he had stage 3 colorectal cancer at 46. He publicly shared his diagnosis a year later. Van Der Beek's death comes weeks after a report revealed that colon cancer has become the leading cause of cancer death in people under 50. In 2020, Chadwick Boseman also died from colorectal cancer, at 43, and Catherine O'Hara , who died from a pulmonary embolism last week at 71, had also been diagnosed with rectal cancer. After announcing his diagnosis, Van Der Beek spoke about the importance of getting screened,
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant Health to Participate in Upcoming Investor ConferencesBusiness Wire
- Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions [Yahoo! Finance]Yahoo! Finance
- Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment DecisionsBusiness Wire
- Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration [Yahoo! Finance]Yahoo! Finance
- Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
GH
Earnings
- 10/29/25 - Beat
GH
Sec Filings
- 2/2/26 - Form 4
- 1/22/26 - Form 4
- 1/22/26 - Form 4
- GH's page on the SEC website